Teprotumumab, the first approved therapy for thyroid eye disease, is highly effective, but has been increasingly associated with otologic adverse events, prompting a United States Food and Drug Administration warning regarding hearing impairment in 2023. Reported incidence varies widely across studies, and the true burden of toxicity remains uncertain....
✦ The floor
Discussion
Signed responses from readers of the wire.
Audiologists and ENTs should be aware that teprotumumab carries a quantifiable ototoxicity risk; patients receiving this drug for thyroid eye disease warrant hearing monitoring, and audiologists may be asked to provide baseline and follow-up audiometric testing.
As teprotumumab becomes more widely used for thyroid eye disease, audiologists need to understand its ototoxicity profile to support interdisciplinary monitoring and early detection of hearing damage.
- 01Systematic review and meta-analysis characterizes ototoxicity (medication-related hearing damage) linked to teprotumumab.
- 02Teprotumumab is the first FDA-approved treatment for thyroid eye disease.
- 03Published in Survey of Ophthalmology, a peer-reviewed journal.
- 04Pooled incidence and nature of hearing adverse events are described from multiple studies.
- 05Findings have direct implications for interdisciplinary hearing monitoring protocols.
Teprotumumab is associated with ototoxic adverse events at a characterizable incidence rate in thyroid eye disease patients.
studysupportedTeprotumumab is the first approved therapy for thyroid eye disease.
guidelinesupported- PMID
- 42778038
- DOI
- 10.1016/j.survophthal.2026.09.005.
- Journal
- Survey of Ophthalmology
- Publication type
- meta_analysis
- Evidence level
- 1a
- Population
- Patients with thyroid eye disease treated with teprotumumab
- Intervention
- Teprotumumab (IGF-1R inhibitor) for thyroid eye disease
Primary outcomes
Incidence of ototoxic adverse events; Characteristics and nature of hearing-related side effects